 |
|
|
  |
02.07.2010 Second Phase III Study
Showed Avastin-Containing Regimen Helped Women with Ovarian Cancer
Live Longer Without their Disease Getting Worse |
Genentech, Inc.,
a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
announced today that a second large, Phase III, international study
showed that the combination of Avastin® (bevacizumab) and
chemotherapy, followed by the continued use of Avastin alone,
increased the time women with previously untreated ovarian cancer
lived without the disease worsening (progression-free survival or
PFS, the primary endpoint), compared to chemotherapy alone. Adverse
events were consistent with those observed in pivotal trials of
Avastin across tumor types for approved indications. Data from the
study, known as ICON7, will be submitted for presentation at an
upcoming medical meeting.
 |
|
|
  |
|
01.07.2010 Oxford BioMedica and
VIB-K.U.Leuven Announce Collaborative Research Project Funded by The
Motor Neurone Disease Association to Develop MoNuDin for Treatment
of Amyotrophic Lateral Sclerosis |
Oxford Biomedica
(LSE:OXB),
the leading UK gene therapy company,
VIB, a life sciences research institute in Flanders,
Belgium and the UK Motor Neurone Disease Association
(MND Association) are pleased to announce the award by
MND Association of a research grant to support the
further preclinical evaluation of MoNuDin®
for the treatment of amyotrophic lateral sclerosis (ALS,
or Lou Gehrig’s disease). The grant is for £255,000 and
will fund a collaborative project between Oxford
BioMedica and the research gro up of Professor Peter
Carmeliet, Director of the VIB Vesalius Research Center
and Professor of Medicine at K.U. Leuven.
|
|
|
 |
|
01.07.2010 MorphoSys Announces Clinical Milestone from Strategic
Alliance |
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) announced
today that it will receive a milestone payment from
Novartis in connection with the initiation of a phase 1
clinical trial, using a HuCAL-derived, fully human
antibody in the therapeutic area of musculoskeletal
diseases. Today's news represents the second
HuCAL-derived antibody to achieve this stage during the
course of 2010, following a clinical milestone hit as
part of the alliance with Centocor in June 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
 |
| |
  |
| |
Innovation Days 2010,
a Pharma & Biotech
event
|
| |
4-5 October 2010
|
|
|
|
Universal Medica Group
is pleased to announce the
Innovation Days 2010,
a Pharma &
Biotech event
to be held in
Paris, on
4th
& 5th
October, 2010. The aim of the
Innovation Days is to bring together people
from Biotech and Pharmaceutical companies,
encourage innovative talent and the
development of bio-industries.
|
|
|
